No Data
No Data
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'This Company Has Never Lost Its Ability To Develop New Medicines'
Weekly Buzz: Finally a Good Week for 2025
Wall Street Today: Trump's on Deck After Market Nearly Hits Year High
Live Stock News: Market Climbs, TikTok Ban Confirmed, Intel for Sale, Week Ends with Positivity
Wall Street Today: Thursday Earnings Looked a Lot More Mixed, and Philly is Booming